1 / 19

Lupin Ltd

Lupin Ltd. Quarter 2 Investor Presentation. Corporate Highlights – Q2 11-12. Net sales grew by 24% to Rs. 17,417 million during Q2, FY 2011-12, up from Rs. 14,094 million (Q2 FY 10-11)

gada
Download Presentation

Lupin Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lupin Ltd Quarter 2 Investor Presentation

  2. Corporate Highlights – Q2 11-12 • Net sales grew by 24% to Rs. 17,417 million during Q2, FY 2011-12, up from Rs. 14,094 million (Q2 FY 10-11) • Net profits grew by 24% to Rs. 2,669 million during Q2, FY 2011-12, as compared to Rs 2,150 million (Q2 FY 10-11) • Growth across all geographies • US business grew by 15.2% in INR terms and 17.8% in USD terms • Japan grew by 13.5% in INR terms and 3.8% in JPY terms • S African business grew at 61.0% in INR terms and 57% in ZAR terms • India Region sales continued to grow at 22.2% • Capex spend at Rs 1,285 million to meet expected demand • Revenue Expenditure on R&D was at Rs. 1,380 Mn., amounting to 7.9% of Net Sales during Q2, FY 2011-12, as against Rs. 1,157 Mn., 8.2% of Net Sales in Q2, FY 2010-11 • During the quarter the company filed one ANDA bringing the Cumulative filings as of Q2, FY 2011-12, to 153 filings, of which 54 have been approved by the US FDA • Metformin ER Tablets launched in the US market with 180 days exclusivity • Licensing agreement entered into with Medicis Pharmaceutical Corporation for applying proprietary technology on multiple products

  3. Financial Trend Q2 2011-12 Sales +24% EBIDTA +35 PAT +24%

  4. Financial Highlights : Q2 11-12

  5. Balance Sheet Ratios Rs Mn

  6. Business Break up Formulations Sales Break up Revenue Mix : Q2 11-12 Geographical Break up

  7. Business Update

  8. Advanced Markets – US and Europe • US Branded • Branded portfolio forms 25% of US Turnover and grew by 19% in the quarter • US Generics • 5th largest Generic player in the U.S. by Rx (IMS Health) – grew by 14% in the quarter • No. 1 in 16 out of 32 products • Top 3 in 30 of the 32 products • EU Generics • Recorded a growth of 25% during the quarter

  9. India Region Formulations • Aggressive focus on brand building • Extensive collaboration with thought leading institutions • Continues to be among the fastest growing company in the domestic space @ 22% • Contributed 29% to Lupin’s overall revenues during Q2, FY 2011-12 • Branded business grew by 23% during the quarter • Current Field Force strength at 4600+ • 4 products find a place among the top 300 in the industry • 11 new products launched in the Quarter

  10. Japan • Net Sales grew by 13.5% at Rs 1,780 Mn and contributed 10% of the revenues during the quarter. Sales in JPY terms grew by 3.8% during the quarter • Market leader in Risperidone in terms of units and key player in Amlodipine • 6 new products launched during the year • Profit enhancement measures to yield better results in the days to come • Work ongoing for 12 manufacturing site transfer projects for cost advantage

  11. South Africa • Net Sales grew by 61% at Rs 679 Mn and contributed 4% of the revenues during the quarter. Sales in ZAR terms grew by 57% during the quarter • Sixth largest generic company in the S African market • Leading presence in CVS • Several new products under registration • Future growth through improved generics, IP challenges and in-licensing • Leaders in Amlodipine, Amloc and Bilocor in unit sales

  12. ROW • New brand launches in Philippines in specialized Oncology portfolio. • Brand acquisition and in-licensing – a common theme across markets • OTC promotion support in mass media • Created thrust in three countries across CIS – Russia, Ukraine and Kazakhstan • Strategic focus on tender / hospital business in CIS • Increased focus on brand building and entry into retail chains

  13. API and Intermediates • Cost, quality and reliability are the cornerstones of our API strategy • Global leadership in chosen therapies • Cephs • Ceph-intermediates • Anti-TB range • Lisinopril • Achieved global cost, capacity and market share leadership in most products • Strategic input into formulations business

  14. Research and Development • Talent pool of 1000+ scientists • 153 ANDAs, 111 DMFs • Ability to churn out rich pipeline across geographies • Increased focus on F2F and Para IV’s • Strength in drug delivery • Litigation Settlements – Loestrin Fe, Femcon Fe, Minocycline • Bioadhesive • Laser-drilled • Matrix/coated • Taste-masking • Revamping Drug Discovery • Requisite infrastructure in place • Total expenditure Q2 2011-12 – Rs. 1,380 Mn, 7.9% of Net sales

  15. US Generics Pipeline • 153 products filed, 54 approved • Para IV’s addressing market size of US$ 30 Bn • F2Fs – Desloratadine, Memantine, Duloxetine, Eszopiclone, Ziprasidone, Lanthanum Carbonate, Pregabalin, Lo-Seasonique, Seasonale • Exclusive F2Fs – Fortamet, Glumetza, Cipro DS • Differentiated products • Oral contraceptives • Ophthalmic • Niche products – Niacin XR, Esomeprazole, Tricor, Sevelamer

  16. The Way Ahead

  17. Lupin’s Core Strength in Generics Managing the Environment Advantage • Local market knowledge • Speed & agility • High quality products • Low cost manufacturing

  18. Focal Points Increase Market Share Increase Margins

  19. Thank You

More Related